# A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible Vaccines

> **NCT00002402** · PHASE1 · COMPLETED · sponsor: **VaxGen** · enrollment: 120 (—)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
- **BIOLOGICAL:** MN rgp120/HIV-1 and A244 rgp120/HIV-1
- **BIOLOGICAL:** Aluminum hydroxide

## Key facts

- **NCT ID:** NCT00002402
- **Lead sponsor:** VaxGen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 120 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002402, "A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible Vaccines". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00002402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*